Tracers / [18F]FAPI-74
[18F]FAPI-74
Also written as [18F]FAPI-74; [F-18]FAPI-74; F-18 FAPI-74; FAPI-74
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 11
What it is
- Compound class
- Radiolabelled quinoline-based FAP-inhibitor (small molecule; Al-F-18 or cold-kit Ga-68 labelled member of the FAPI-46 family)
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 32591493
- Clinical application
- Tumour-stroma imaging (FAP-family applications) PMID 32591493
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| AllinOne (AiO) Trasis | vendor cassette | SPE | 63.0 ± 9.2% | 99.8 ± 0.1% | FAPI- 74 SOFIE | 40272498 2025 Eur J Nucl Med Mol Imaging The radiosynthesis of [18F]F-FAPI- 74 was performed on an AllinOne module (Trasis, Liège, Belgium) using a FAPI- 74 cassette and reagent kit (Trasis, Liège, Belgium). — The short sequence yielded radioactivity yields (RAY) of 63.0 ± 9.2% (n = 36) |
| — | — | — | — | — | — | 42318157 2026 Oncol Rev |
| — | — | — | — | — | — | 42228299 2026 Int J Clin Oncol |
| Manual synthesis | — | HPLC+SPE | 12.3 ± 6.6% no | >99% | FAPI-74 precursor | 41779297 2026 EJNMMI Res [18F]F-FAPI-74 radiolabeling was performed according to Naka et al. [25] with minor procedural modifications — [18F]F-FAPI-74 radiolabeling achieved an activity yield of 12.3 ± 6.6% (non-decay corrected, n = 8) |
| — | — | — | — | — | — | 41599688 2026 Pharmaceuticals (Basel) |
| — | — | SPE | — | — | NOTA-FAPI-74 | 41025439 2025 J Am Heart Assoc |
| AllinOne (AiO) Trasis | vendor cassette | SPE | 63.0 ± 9.2% | 99.8 ± 0.1% | FAPI- 74 SOFIE | 40272498 2025 Eur J Nucl Med Mol Imaging The radiosynthesis of [18F]F-FAPI- 74 was performed on an AllinOne module (Trasis, Liège, Belgium) using a FAPI- 74 cassette and reagent kit (Trasis, Liège, Belgium). — The short sequence yielded radioactivity yields (RAY) of 63.0 ± 9.2% (n = 36) |
| — | — | — | — | — | — | 40148277 2025 Nat Commun |
| — | — | — | — | — | — | 39956945 2025 J Cachexia Sarcopenia Muscle |
| — | — | — | — | — | — | 42148857 2026 Clin Nucl Med |
| — | — | — | — | — | — | 41544886 2026 Vet J |
Precursor
- Common precursor
- FAPI-74 PMID 40272498 (DOI 10.1007/s00259-025-07239-6)
- Suppliers seen in the literature
- SOFIE (Dulles, VA, USA)
- Cited suppliers in indexed syntheses
- SOFIE
- Typical final purification
- SPE
Need this precursor?We can point you to suppliers for [18F]FAPI-74, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FAPI-74.
Get in touchNotes
Added from reverse module search (stage 6); 9 article(s) with F-18.